Método para promover inmunoterapias

Uso de una sustancia activa que enlaza Fcg-para la preparación de un medicamento para el tratamiento de cáncer, en cuyo caso el tratamiento comprende los pasos de: a) preparar una muestra de sangre de un paciente; b) someter la muestra de sangre a una inmunoaféresis así como administrar al paciente...

Full description

Saved in:
Bibliographic Details
Main Authors NOCKEN, FRANK, HEPPER, MARTIN, LEINENBACH, HANS
Format Patent
LanguageSpanish
Published 30.07.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Uso de una sustancia activa que enlaza Fcg-para la preparación de un medicamento para el tratamiento de cáncer, en cuyo caso el tratamiento comprende los pasos de: a) preparar una muestra de sangre de un paciente; b) someter la muestra de sangre a una inmunoaféresis así como administrar al paciente la muestra de sangre tratada de esta manera; c) administrar el medicamento al paciente, en cuyo caso la sustancia activa que enlaza el Fcg-receptor es un anticuerpo monoclonal y/o recombinante el cual está dirigido contra antígenos asociados a cáncer. Ex-vivo procedure for increasing the efficacy of active substances binding to antibodies and Fcgamma -receptors, comprises: (a) preparing a blood sample of a patient; (b) subjecting the blood sample to an immunophoresis; and (c) administering an antibody or an Fcgamma -receptor binding active substance to a patient. Independent claims are included for: (1) use of a combination of one or more medicaments with FcR-binding immunoglobulins, fragments of immunoglobulin or fusion proteins, for producing a medicament for treating cancer, autoimmune diseases, transplanted patients and/or for vaccinating against viruses, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to an immunophoresis and administering an antibody to a patient; (2) use of specific ligands for body's own antibodies with Fcgamma -receptor binding regions, for producing a column, which exhibits the specific ligand that is coupled to it, for treating a patient with Fcgamma -receptor binding active substances, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to an immunophoresis and administering Fcgamma -receptor binding active substances to a patient; (3) use of specific ligands for body's own antibodies for producing a column, which exhibits the ligand that is coupled to it, for treating a patient with antibodies, where the treatment comprises: (a) preparing a blood sample of a patient; (b) subjecting the blood sample to an immunophoresis; (c) administering an antibody to a patient; (4) use of specific ligands for cancer-associated antigens soluble in blood sample for producing a column, which exhibits the ligand that is coupled to it, for treating a patient with therapeutic antibodies, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to an immunophoresis and administering an antibody to a patient; and (5) use of Fcgamma -receptor binding active substances for producing a medicaments for treating cancer, autoimmune diseases, transplanted patients and/or for vaccinating against viruses, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to a immunophoresis and administering the medicament to the patients. ACTIVITY : Cytostatic; Immunosuppressive. MECHANISM OF ACTION : None given.
Bibliography:Application Number: ES20070802220T